MedTrace Logo

Biomarker Analysis in Post-COVID Patients

NCT05836428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2023-05-01

No results posted yet for this study

Summary

Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.

Conditions

  • Post-COVID-19 Syndrome

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Laura de Boni, MD · DLR German Aerospace Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2023-04-26
Completion
2023-04-26

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05836428 on ClinicalTrials.gov